This suggests either that non-epoxide metabolites of the PUFA are responsible for effecting these changes in tumor progression, or more likely, that because of reduced levels of EPHX2 in females, TCDD treatment induces sufficient increases in PUFA epoxides even in the absence of EPHX2 inhibition to impact tumor growth and metastasis. This evidence concerns the gene EPHX2 and neoplasm.